All Stories

  1. Contribution of Peripheral Microvascular Dysfunction to Mild Cognitive Impairment
  2. Subjective cognitive complaints in White and African American older adults: associations with demographic, mood, cognitive, and neuroimaging features
  3. Effects of candesartan on cerebral microvascular function in mild cognitive impairment: Results of two clinical trials
  4. Development of digital voice biomarkers and associations with cognition, cerebrospinal biomarkers, and neural representation in early Alzheimer's disease
  5. Safety and biomarker effects of candesartan in non-hypertensive adults with prodromal Alzheimer’s disease
  6. Association of Plasma and Cerebrospinal Fluid Alzheimer Disease Biomarkers With Race and the Role of Genetic Ancestry, Vascular Comorbidities, and Neighborhood Factors
  7. Candesartan is associated with lower amyloid accumulation in non‐hypertensive prodromal Alzheimer’s disease
  8. Perceived stress increases Alzheimer's disease risk in African Americans
  9. Effects of Candesartan vs Lisinopril on Neurocognitive Function in Older Adults With Executive Mild Cognitive Impairment
  10. 18F-Flortaucipir PET Associations with Cerebrospinal Fluid, Cognition, and Neuroimaging in Mild Cognitive Impairment due to Alzheimer’s Disease
  11. Modeling Cerebral Hemodynamics Using BOLD Magnetic Resonance Imaging and its Application in Mild Cognitive Impairment
  12. P4-293: COMPARISON OF FLORTAUCIPIR PET WITH CEREBROSPINAL FLUID, COGNITIVE FUNCTIONING AND NEUROIMAGING MEASURES IN MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER'S DISEASE
  13. Design Elements and Enrollment Patterns of Contemporary Trials in Heart Failure With Preserved Ejection Fraction
  14. Evolving Landscape of Clinical Trials in Heart Failure: Patient Populations, Endpoint Selection, and Regions of Enrollment
  15. Globalization of heart failure clinical trials: a systematic review of 305 trials conducted over 16 years